EMA recommends suspension of 17-OHPC medicines in EU

2024-05-20

上市批准加速审批

EMA recommends suspension of 17-OHPC medicines in EU

Preview

来源: Pharmaceutical Technology

In some EU countries, 17-OHPC medicines have been authorised as injections for preventing pregnancy loss or premature birth. Credit: Victoria Moloman / Shutterstock.com.

The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has advised the suspension of marketing authorisations for therapeutics containing 17-hydroxyprogesterone caproate (17-OHPC) in the European Union (EU).

The recommendation follows a review that raised concerns about an as-yet unconfirmed risk of cancer in individuals exposed to 17-OHPC in the womb.

The PRAC review included a large population-based study spanning 50 years.

Despite the low number of cancer cases and limitations such as insufficient information on cancer risk factors, the committee concluded that a possible cancer risk could not be ruled out.

In addition to cancer risk concerns, new studies have indicated that 17-OHPC is ineffective in preventing premature birth.

See Also:NICE recommends Rhythm’s Imcivree for rare genetic obesity disorder

Preview

来源: Pharmaceutical Technology

Glenmark to market BeiGene’s oncology medicines in India

Preview

来源: Pharmaceutical Technology

PRAC examined a study involving more than 1,700 pregnant women with a history of preterm delivery which found that 17-OHPC did not outperform a placebo in preventing recurrent preterm births or related medical complications in newborns.

Two published meta-analyses further confirmed the lack of efficacy in preventing preterm birth.

For other authorised uses of 17-OHPC, such as the treatment of gynaecological and fertility disorders, PRAC found limited evidence of effectiveness.

The committee’s review process also included consultations with experts in obstetrics, gynaecology, fertility treatment, and patient representatives.

In some EU countries, 17-OHPC medicines have been authorised as injections for preventing pregnancy loss or premature birth in pregnant women. They are also used for treating conditions related to progesterone deficiency.

In a media statement, EMA said: “In view of the concern raised by the possible risk of cancer in people exposed to 17-OHPC in the womb, together with the data on the effectiveness of 17-OHPC in its authorised uses, PRAC considered that the benefits of 17-OHPC do not outweigh its risks in any authorised use.

“The committee is therefore recommending the suspension of the marketing authorisations for these medicines. Alternative treatment options are available.”

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构